-
Mashup Score: 166Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma - PubMed - 14 day(s) ago
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment li …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 1Early quantification of anti-CD19 CAR T-cells by flow cytometry predicts response in R/R DLBCL - 7 month(s) ago
Viktoria Blumenberg, Busch Galina, Stephan Baumann, Regina Jitschin, Gloria Iacoboni, Eva Hoster, Laura Gallur, Josu Iraola-Truchuelo, Michael Winkelmann, Konst
Source: ashpublications.orgCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 4Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study - 8 month(s) ago
Key Points. Tafasitamab and lenalidomide yielded a considerably lower PFS and OS in DLBCL in the real-world setting compared to the L-MIND trial.Age over 70, EC
Source: ashpublications.orgCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2
Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most frequent complications after CAR T-cell therapy. Most of these infections are bacterial, although viral infections can also occur in this setting. Adenovirus-induced hemorrhagic cystitis is a rare infectious complication and is usually observed after bone marrow or solid organ transplantation. Herein we report a case of adenovirus-induced hemorrhagic cystitis in a patient experiencing urinary symptoms within the first month after CAR T-cell infusion. Based on our experience and a literature review, we discuss the diagnostic approach and potential treatment options for this infrequent infection after CAR T-cell therapy.
Source: www.futuremedicine.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1ESH - European School of Haematology - 12 month(s) ago
2nd How I Manage:CAR-T Therapies and Bispecific Antibodies for my patients September 29-October 1, 2023 – Berlin, Germany #ESHCART2023 Chairs: Ulrich Jäger, Marie JosĂ© Kersten, Loretta Nastoupil ABOUT THE CONFERENCE: CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies. The programme of this ESH conference aims to provide an overview…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 10GELLC - Grupo Español de Leucemia LinfocĂtica CrĂłnica - 1 year(s) ago
leucemia linfocĂtica aguda, leucemia, gellc, grupo trabajo leucemia linfocĂtica aguda, leucemia linfocĂtica
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Anakinra for refractory CRS or ICANS after CAR T-cell therapy - 1 year(s) ago
Chimeric antigen receptor-engineered (CAR) T-cell therapy remains limited by significant toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). The optimal management of severe and/or refractory CRS/ICANS remains ill-defined. Anakinra has emerged as a promising agent based on preclinical data, but its safety and efficacy in CAR…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 7Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists - 1 year(s) ago
TO THE EDITOR:
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma - 1 year(s) ago
Key Points. Bridging therapy (BT) is safe, and complete/partial response to BT confers a 42% reduction in risk of progression/death post-CD19CAR-TGood response
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1
TO THE EDITOR:
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet
Published today in @BloodJournal 🎉 Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma #CART #lymsm Great collaboration with French colleagues @HouotRoch @LysaLymphoma @pebarba https://t.co/JHytnC319w